Renaissance Technologies LLC Decreases Holdings in Delcath Systems, Inc. $DCTH

Renaissance Technologies LLC lowered its position in Delcath Systems, Inc. (NASDAQ:DCTH) by 57.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,300 shares of the company’s stock after selling 206,299 shares during the period. Renaissance Technologies LLC’s holdings in Delcath Systems were worth $1,441,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Rosalind Advisors Inc. grew its holdings in Delcath Systems by 13.8% in the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after purchasing an additional 400,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Delcath Systems by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company’s stock worth $17,817,000 after buying an additional 46,693 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Delcath Systems in the 3rd quarter worth about $7,164,000. Goldman Sachs Group Inc. boosted its position in shares of Delcath Systems by 116.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock worth $5,936,000 after buying an additional 315,583 shares in the last quarter. Finally, ExodusPoint Capital Management LP grew its stake in Delcath Systems by 30.9% in the 4th quarter. ExodusPoint Capital Management LP now owns 496,705 shares of the company’s stock valued at $5,017,000 after acquiring an additional 117,122 shares during the last quarter. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Positive analyst revisions: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects DCTH to lose $0.17 per share in fiscal 2026, versus a prior estimate of a $0.88 loss, and projects a return to profitability in fiscal 2027. Longer-term estimates were also increased, including 2028 EPS of $0.56, 2029 EPS of $0.97 and 2030 EPS of $1.46. MarketBeat analyst estimates
• Positive Sentiment: Zacks upgraded DCTH: Zacks Research moved its rating from “Hold” to “Strong Buy,” citing improving earnings expectations and recent price strength. Zacks rating update
• Positive Sentiment: Momentum remains favorable: Zacks identified Delcath as a candidate for trend and momentum investors, indicating that the stock has outperformed enough to pass its recent-price-strength screens. Zacks trend investor article
• Neutral Sentiment: Short-interest data offers little signal: Reported short interest was zero shares, unchanged from the prior period, with a zero-day short ratio. The accompanying claim of a “significant increase” appears inconsistent with the figures, so it is unlikely to explain current trading.
• Negative Sentiment: Near-term valuation and technical risk: DCTH is trading close to its 52-week high after a substantial run-up. With the company still expected to post a loss in the near term, investors may be taking profits or waiting for additional execution before pushing the stock higher.

Delcath Systems Trading Down 0.6%

NASDAQ:DCTH opened at $17.11 on Thursday. The firm has a market cap of $593.72 million, a price-to-earnings ratio of 1,712.71 and a beta of 0.52. The company’s 50-day moving average is $12.75 and its two-hundred day moving average is $11.02. Delcath Systems, Inc. has a 12-month low of $8.12 and a 12-month high of $17.42.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $29.13 million during the quarter, compared to the consensus estimate of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. On average, equities research analysts forecast that Delcath Systems, Inc. will post -0.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

DCTH has been the subject of a number of research reports. Zacks Research upgraded shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a research report on Monday. BTIG Research raised their price objective on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research report on Friday, August 7th. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.17.

Delcath Systems Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.